iNtRON Biotechnology, Inc. (048530.KQ)
KRW 5500.0
(-4.35%)
KRW 5500.0
(-4.35%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.56 Billion KRW | -46.05% |
| 2022 | 8.45 Billion KRW | -58.86% |
| 2021 | 20.55 Billion KRW | -18.71% |
| 2020 | 25.28 Billion KRW | 840.1% |
| 2019 | 2.68 Billion KRW | -81.4% |
| 2018 | 14.45 Billion KRW | 230.42% |
| 2017 | 4.37 Billion KRW | -2.34% |
| 2016 | 4.48 Billion KRW | -41.88% |
| 2015 | 7.7 Billion KRW | 0.0% |
| 2012 | 3.53 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 730.91 Million KRW | -68.27% |
| 2024 Q2 | 850.57 Million KRW | 16.37% |
| 2023 FY | 4.56 Billion KRW | -46.05% |
| 2023 Q3 | 444.86 Million KRW | -52.38% |
| 2023 Q4 | 2.3 Billion KRW | 417.8% |
| 2023 Q2 | 934.27 Million KRW | -6.78% |
| 2023 Q1 | 1 Billion KRW | -12.88% |
| 2022 Q3 | 1.56 Billion KRW | -1.32% |
| 2022 FY | 8.45 Billion KRW | -58.86% |
| 2022 Q4 | 1.15 Billion KRW | -26.33% |
| 2022 Q2 | 1.58 Billion KRW | -61.96% |
| 2022 Q1 | 4.16 Billion KRW | -29.67% |
| 2021 Q1 | 4.41 Billion KRW | -42.85% |
| 2021 FY | 20.55 Billion KRW | -18.71% |
| 2021 Q4 | 5.91 Billion KRW | 37.84% |
| 2021 Q2 | 6.21 Billion KRW | 40.72% |
| 2021 Q3 | 4.29 Billion KRW | -30.96% |
| 2020 Q3 | 3.11 Billion KRW | -77.98% |
| 2020 FY | 25.28 Billion KRW | 840.1% |
| 2020 Q4 | 7.72 Billion KRW | 147.81% |
| 2020 Q1 | 1.43 Billion KRW | 45.51% |
| 2020 Q2 | 14.16 Billion KRW | 886.96% |
| 2019 FY | 2.68 Billion KRW | -81.4% |
| 2019 Q4 | 986.46 Million KRW | 33.61% |
| 2019 Q3 | 738.34 Million KRW | -42.15% |
| 2019 Q2 | 1.27 Billion KRW | 81.96% |
| 2019 Q1 | 701.37 Million KRW | -94.3% |
| 2018 FY | 14.45 Billion KRW | 230.42% |
| 2018 Q2 | 1.02 Billion KRW | -17.44% |
| 2018 Q1 | 1.24 Billion KRW | -3.55% |
| 2018 Q3 | 508.25 Million KRW | -50.41% |
| 2018 Q4 | 12.29 Billion KRW | 2319.0% |
| 2017 Q1 | 1.27 Billion KRW | 0.1% |
| 2017 FY | 4.37 Billion KRW | -2.34% |
| 2017 Q4 | 1.28 Billion KRW | 13.41% |
| 2017 Q3 | 1.13 Billion KRW | -8.73% |
| 2017 Q2 | 1.24 Billion KRW | -2.17% |
| 2016 FY | 4.48 Billion KRW | -41.88% |
| 2016 Q4 | 1.26 Billion KRW | 15.0% |
| 2016 Q3 | 1.1 Billion KRW | -17.97% |
| 2016 Q2 | 1.34 Billion KRW | 5.72% |
| 2016 Q1 | 1.27 Billion KRW | 0.0% |
| 2015 FY | 7.7 Billion KRW | 0.0% |
| 2013 Q3 | 1.06 Billion KRW | -3.03% |
| 2013 Q2 | 1.09 Billion KRW | -16.66% |
| 2013 Q1 | 1.31 Billion KRW | 78.37% |
| 2012 FY | 3.53 Billion KRW | 0.0% |
| 2012 Q4 | 736.05 Million KRW | -19.34% |
| 2012 Q3 | 912.5 Million KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Co., Ltd. | -6.01 Billion KRW | 175.857% |
| BINEX Co., Ltd. | 56.65 Billion KRW | 91.95% |
| Bioneer Corporation | 199.25 Billion KRW | 97.711% |
| Anterogen.Co.,Ltd. | 2.21 Billion KRW | -106.054% |
| MEDIPOST Co., Ltd. | 40.18 Billion KRW | 88.65% |
| CrystalGenomics, Inc. | 1.45 Billion KRW | -213.031% |
| Helixmith Co., Ltd | 2.12 Billion KRW | -114.948% |
| Chabiotech Co.,Ltd. | 255.19 Billion KRW | 98.213% |
| Medy-Tox Inc. | 128.16 Billion KRW | 96.441% |
| Peptron, Inc. | 1.14 Billion KRW | -299.873% |
| Amicogen, Inc. | 51.51 Billion KRW | 91.146% |
| Genexine, Inc. | 387.48 Million KRW | -1077.045% |
| HLB Therapeutics Co.,Ltd. | 6.69 Billion KRW | 31.869% |
| LegoChem Biosciences, Inc. | 17.79 Billion KRW | 74.373% |
| ALTEOGEN Inc. | 31.19 Billion KRW | 85.381% |
| PharmaResearch Co., Ltd. | 182.25 Billion KRW | 97.498% |
| SillaJen, Inc. | 1.45 Billion KRW | -213.087% |
| JETEMA, Co., Ltd. | 26.58 Billion KRW | 82.842% |
| OliX Pharmaceuticals,Inc | 14.42 Billion KRW | 68.376% |
| Genomictree Inc. | -1.03 Billion KRW | 539.139% |
| MedPacto, Inc. | -1.83 Billion KRW | 348.866% |
| D&D Pharmatech | 18.67 Billion KRW | 75.58% |
| EASY BIO,Inc. | 50.88 Billion KRW | 91.037% |
| GI Innovation, Inc. | 1.98 Billion KRW | -129.256% |